Pixium Vision announces the implementation of a financing of a maximum nominal amount of €30 million, and the drawdown of a first tranche of €5.5 million. .
Pixium Vision expands its Board of Directors with the appointment of Anja Krammer and August Moretti Paris, France, June 24, 2022 – 07:00 CET – Pixium.
/PRNewswire/ Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic therapies for treatment of retinal degenerative.
Pixium Vision announces its cash position at 31 March 2022 and provides an update on its activities and financial outlook until the end of 2022 Paris,.